Beta-Blockers Skin Side Effects: Key Insights

Beta-blockers, also known as beta-adrenergic blocking agents, are a class of medications primarily used to manage cardiovascular conditions such as hypertension, angina, arrhythmias, and heart failure by blocking the effects of adrenaline on beta receptors in the heart and blood vessels. While effective for these indications, beta-blockers are associated with a range of cutaneous adverse effects that dermatologists must recognize and manage. This article details the skin-related side effects of beta-blockers, including their mechanisms, clinical presentations, and therapeutic implications in dermatology. Additionally, it explores the evolving role of both systemic and topical beta-blockers in treating various dermatological conditions.

What are the cutaneous adverse effects of beta-blockers?

Beta-blockers can induce or exacerbate several skin conditions, with psoriasis being the most well-recognized. These effects arise due to the drugs’ interference with adrenergic signaling, which influences immune responses, vascular tone, and epidermal proliferation. Common cutaneous adverse effects include:

• Psoriasis: Beta-blockers are a well-recognised trigger to exacerbate or precipitate psoriasis. They can induce psoriasiform eruptions in patients without prior history or worsen existing disease. Clinical presentation includes sharply demarcated erythematous plaques with silvery scales, often on elbows, knees, trunk, and back. Nail pitting may also occur. Onset typically occurs 1-18 months after initiation, with flares resolving 1-5 weeks post-discontinuation.
• Raynaud phenomenon: Exacerbation of Raynaud phenomenon is commonly reported in patients taking beta-blockers, due to peripheral vasoconstriction from non-selective beta-blockade. Patients experience cold extremities, color changes in fingers/toes (white, blue, red), and pain.
• Alopecia: Alopecia due to beta-blockers is a telogen effluvium, a reversible thinning of the hair resulting from premature shift of hair follicles to the resting phase. It affects scalp diffusely and resolves upon drug cessation.
• Nail deformity: Beta-blockers have been linked to nail changes such as pitting, similar to psoriatic nails, though less common.
• Lichenoid drug eruptions: These present as pruritic, polygonal papules resembling lichen planus, often on extremities and trunk.

Other reported reactions include exanthematous rashes, urticaria (hives), and rarely severe conditions like Stevens-Johnson syndrome or toxic epidermal necrolysis with propranolol. Mechanisms for psoriasis induction may involve delayed hypersensitivity, immunological alterations, or disruption of cyclic adenosine monophosphate pathways.

Psoriasis

Psoriasis exacerbation by beta-blockers is well-documented in clinical literature. In one case, a 46-year-old female on metoprolol developed widespread plaques on extremities, trunk, buttocks, and back, with nail pitting, sparing face, hands, and feet. Prior over-the-counter treatments failed, and biopsy confirmed psoriasis. Discontinuing the beta-blocker and initiating narrowband UVB phototherapy plus topical triamcinolone led to marked improvement within weeks. Studies show patients with psoriasis are more prone to uncontrolled hypertension, complicating management. Beta-blockers should be avoided in psoriatic patients when possible, opting for alternatives like calcium channel blockers (though these carry rosacea risk).

Raynaud phenomenon

Non-selective beta-blockers like propranolol worsen Raynaud phenomenon by causing vasoconstriction via unopposed alpha-adrenergic activity. Patients report cold hands/feet, a frequent side effect. This is particularly problematic in those with preexisting Raynaud’s. Selective beta-1 blockers (e.g., atenolol) may pose lower risk. Management involves switching agents or vasodilators like calcium channel blockers.

Alopecia

Beta-blocker-induced alopecia manifests as telogen effluvium, with diffuse shedding 2-3 months post-onset. It is reversible, with regrowth occurring 3-6 months after discontinuation. Propranolol and acebutolol are commonly implicated.

Nail deformity

Nail changes include psoriasis-like pitting and onycholysis, often accompanying skin flares. These resolve with treatment of the underlying eruption.

Lichenoid drug eruptions

These eruptions mimic lichen planus with violaceous papules, Wickham striae, and koebnerization. They occur weeks to months after starting therapy and improve upon withdrawal.

Other adverse skin reactions

• Exanthematous rashes: Widespread maculopapular eruptions.
• Urticaria: Acute hives, resolving quickly post-discontinuation.
• Cold extremities: Due to vasoconstriction.
• Rare severe reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis.

Abrupt withdrawal of beta-blockers can induce rebound tachycardia, hypertension, or angina, but skin-specific rebound like psoriasis flare may occur if steroids were involved.

Therapeutic uses of beta-blockers in dermatology

Beyond adverse effects, beta-blockers have therapeutic applications, particularly propranolol and topical timolol.

Infantile haemangiomas

Oral propranolol is first-line for problematic infantile haemangiomas (IH), reducing size and erythema via vasoconstriction, apoptosis of capillary endothelial cells, and angiogenesis inhibition. Used for critical sites like periocular, nasal tip. Side effects: hypoglycemia, bradycardia, hypotension (monitor in infants). Topical timolol 0.5% gel is effective for superficial IH, with fewer systemic effects.

Rosacea and flushing

Propranolol reduces symptomatic flushing in erythematotelangiectatic rosacea by beta-2 blockade-induced vasoconstriction. Studies show significant improvement in 3-21 days. Beta-blockers slightly decrease rosacea risk overall. Topical timolol reduces erythema and telangiectasia.

Acne and post-acne erythema

Topical timolol 0.5% reduces acne lesions (comedones, papules, pustules) and severity. For post-acne erythema, it significantly improves redness and pigmentation.

Other uses

• Infantile haemangiomas of critical sites.
• Post-radiation alopecia prevention.
• Adjunct in Kaposi sarcoma, pyogenic granuloma.

Management strategies

For adverse effects: Discontinue or switch beta-blockers (e.g., to atenolol for psoriasis). Treat flares with topicals (corticosteroids), phototherapy. For therapeutic use: Titrate doses, monitor vitals, especially in children. Topical formulations minimize systemic risks.

Frequently asked questions

Can beta-blockers cause psoriasis?

Yes, beta-blockers commonly exacerbate or induce psoriasis, presenting as scaly plaques 1-18 months after starting therapy.

Do beta-blockers worsen Raynaud’s?

Yes, particularly non-selective ones, causing cold extremities and vasospasm.

Is beta-blocker hair loss reversible?

Yes, it is telogen effluvium and reverses after discontinuation.

Are topical beta-blockers safe for skin conditions?

Yes, timolol shows efficacy in haemangiomas, rosacea, acne with mainly local side effects like erythema.

Should psoriasis patients avoid beta-blockers?

Yes, opt for alternatives to prevent flares.

Similar Articles

Alarming Rise in Self-Harm in Young People

Alarming Rise in Self-Harm in Young People

Skin Signs Of Non-Accidental Injury: Expert Guide For Clinicians

Lichen Simplex Of The Scrotum: Diagnosis And Treatment

Labial Adhesion In Prepubertal Girls: What Parents Need To Know

Thrush In Men: 5 Signs, Causes, And Treatment Options

Author

medha deb

 

Medha Deb is an editor with a master's degree in Applied Linguistics from the University of Hyderabad. She believes that her qualification has helped her develop a deep understanding of language and its application in various contexts.

Read full bio of medha deb